The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin

首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin

【24h】

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin

机译：遗传变异对HCV-4埃及患者接受Sofosbuvir / daclatasvir和利巴韦林的HCV-4埃及患者治疗反应的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This study aimed to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in ribavirin (RBV) transport (SLC28A2 gene, ABCB1 gene and ABCB11 gene) on the clinical outcome and pharmacokinetics of ribavirin in HCV- 4 Egyptian patients.

机译：目的：本研究旨在探讨有核苷酸（RBV）转运（SLC28A2基因，ABCB1基因和ABCB11基因）参与的基因的单核苷酸多态性（SNP）对HCV-4埃及患者利巴韦林的临床结果和药代动力学的影响。

著录项

来源
《Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie》 |2020年第2020期|共9页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
Ribavirin; Pharmacokinetics; ABCB1; ABCB11; Hepatitis C; SNP;

机译：利巴林;药代动力学;ABCB1;ABCB11;丙型肝炎;SNP;

相似文献

外文文献
中文文献
专利

1. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin [J] . Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie . 2020,第期

机译：遗传变异对HCV-4埃及患者接受Sofosbuvir / daclatasvir和利巴韦林的HCV-4埃及患者治疗反应的影响
2. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy [J] . Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, The European journal of health economics: HEPAC : health economics in prevention and care . 2018,第1期

机译：Daclatasvir + Sofosbuvir +利巴韦林（16周和12周）使用的成本效益分析与Sofosbuvir +利巴韦林（16周和24周）治疗意大利丙型肝炎病毒基因型3的肝硬化患者治疗
3. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients [J] . European journal of gastroenterology and hepatology . 2020,第8期

机译：在埃及患者的队列中使用Sofosbuvir和Daclatasvir治疗丙型肝炎治疗过程中的发病率和死亡率，在埃及患者的队列中
4. HLA-C gene in Hepatitis C Virus infected Patients in Egypt, to estimate the relation between HLA-C gene and Interferon/Ribavirin as treatment for hepatitis C virus [C] . SHADEN MUAWIA HANAFY, AMAL AHMED ABBAS, SAFY KABEEL ALY MANSOUR International Conference on Cellular and Molecular Biology, Biophysics and Bioengineering . 2015

机译：HLA-C基因在丙型肝炎病毒中感染埃及患者，估计HLA-C基因和干扰素/利巴韦林与丙型肝炎病毒治疗的关系
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection [O] . Ossama A Ahmed, Mohamed A Elsebaey, Mohamed Hassan A Fouad, 2018

机译：埃及索非布韦联合达卡他韦联合利巴韦林或不联合利巴韦林治疗的结果和预测因素患者均感染基因型4型丙型肝炎病毒
7. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection [O] . Ossama A. Ahmed, Mohamed A Elsebaey, Mohamed Hassan Ahmed Fouad, 2018

机译：与埃及患者基因型4丙型肝炎病毒感染的埃及患者有或没有利巴韦林治疗反应的结果和预测因子。

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin

摘要

著录项

相似文献

相关主题

期刊订阅